sur TRANSGENE (EPA:TNG)
Transgene raises funds with the Talisman project
Transgene SA, a French biopharmaceutical company, has announced a share issue as part of the Talisman project. This project involves a capital increase through public and private offerings. The expected gross amount is approximately €105 million, including an offering to individual investors via the PrimaryBid platform.
The main objective is to finance the acceleration of the myvac® program, developed in the field of cancer. Planned over several years, the funds are intended to cover phase 2 of the clinical trial and the launch of a new phase 1 trial.
The issuance will be carried out on Euronext Paris at a price not exceeding €1.36 per share. Transgene emphasizes that trading in its shares will be temporarily suspended to ensure a smooth transition of the transaction.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TRANSGENE